Patents by Inventor Zhengwei Peng

Zhengwei Peng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230091366
    Abstract: Disclosed are an APR protection method and device, and a computer storage medium. A preamplifier PA of each of two optical amplifier units at two ends of a transmission line is connected to a booster amplifier BA of the other amplifier unit by an optical fiber. The method comprises: when a reception state of PA of at least one of two amplifier units is a loss of signal state and a switch chip of said amplifier unit detects a link interruption signal, activating an APR protection state of said amplifier unit which is to turn off BA output of said amplifier unit; when the switch chip of at least one of two amplifier units detects a link conduction signal, deactivating the APR protection state of the present amplifier unit to restore a state of BA of said amplifier unit to a state before the APR protection state is activated.
    Type: Application
    Filed: December 28, 2020
    Publication date: March 23, 2023
    Inventors: Qi ZHOU, Zhaoxia LIU, Ying ZHANG, Tao YUAN, Jiekui YU, Chuanbin ZHANG, Zhengwei PENG, Feifei HE
  • Publication number: 20060063932
    Abstract: Novel aminoalkylpyrrolidine 5-HT7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites or prodrugs thereof.
    Type: Application
    Filed: September 19, 2005
    Publication date: March 23, 2006
    Inventors: Yuanjin Rui, Atsuo Kuki, Yufeng Hong, Zhengwei Peng, David Luthin
  • Publication number: 20040092747
    Abstract: Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Application
    Filed: July 17, 2003
    Publication date: May 13, 2004
    Inventors: Steven Lee Bender, Dilip Bhumaralkar, Michael Raymond Collins, Stephen James Cripps, Judith Gail Deal, Lei Jia, Mitchell David Nambu, Cynthia Louise Palmer, Zhengwei Peng, Michael David Varney
  • Publication number: 20040044037
    Abstract: Novel amidino-urea 5-HT7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites, or prodrugs thereof.
    Type: Application
    Filed: April 29, 2003
    Publication date: March 4, 2004
    Inventors: Yufeng Hong, Atsuo Kuki, Eileen Valenzuela Tompkins, Zhengwei Peng, David Robert Luthin
  • Publication number: 20040039044
    Abstract: Novel aminoalkylpyrrolidine 5-HT7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites, or prodrugs thereof.
    Type: Application
    Filed: April 29, 2003
    Publication date: February 26, 2004
    Inventors: Yuanjin Rui, Atsuo Kuki, Yufeng Hong, Zhengwei Peng, David Robert Luthin
  • Patent number: 6635641
    Abstract: Amide compounds represented by the formula: wherein: R1 is a moiety represented by the formula  where X is selected from the group consisting of CH2, O, S, and NH; and Y is selected from the group consisting of CH2, O, and S, provided that at least one of X and Y is CH2, or X and Y together with the bond there-between form a cyclopropyl; are described. These compounds and pharmaceutical compositions containing them modulate and/or inhibit the activity of certain protein kinases and are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: October 21, 2003
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Steven Lee Bender, Dilip Bhumralkar, Michael Raymond Collins, Stephen James Cripps, Judith Gail Deal, Lei Jia, Mitchell David Nambu, Cynthia Louise Palmer, Zhengwei Peng, Michael David Varney
  • Patent number: 6620828
    Abstract: Diaminothiazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: September 16, 2003
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Shao Song Chu, Larry Andrew Alegria, Steven Lee Bender, Suzanne Pritchett Benedict, Allen J. Borchardt, Robert Steve Kania, Mitchell David Nambu, Anna Maria Tempczyk-Russell, Sepehr Sarshar, Dilip Bhumralkar, Zhengwei Peng, Michelle Yang
  • Publication number: 20020103203
    Abstract: Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Application
    Filed: January 19, 2001
    Publication date: August 1, 2002
    Inventors: Steven Lee Bender, Dilip Bhumralkar, Michael Raymond Collins, Stephen James Cripps, Judith Gail Deal, Lei Jia, Mitchell David Nambu, Cynthia Louise Palmer, Zhengwei Peng, Michael David Varney
  • Publication number: 20020025976
    Abstract: Diaminothiazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Application
    Filed: February 15, 2001
    Publication date: February 28, 2002
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Shao Song Chu, Larry Andrew Alegria, Steven Lee Bender, Suzanne Pritchett Benedict, Allen J. Borchardt, Robert Steve Kania, Mitchell David Nambu, Anna Maria Tempczyk-Russell, Sepehr Sarshar, Dilip Bhumralkar, Zhengwei Peng, Michelle Yang